Arrowhead Pharmaceuticals’ (ARWR) “Buy” Rating Reaffirmed at Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $115.00 price objective on the biotechnology company’s stock. Chardan Capital’s price objective points to a potential upside of 96.58% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. JPMorgan Chase & Co. lifted their price objective on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and set a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Leerink Partners lifted their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th. Finally, Morgan Stanley lifted their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $99.07.

Arrowhead Pharmaceuticals Trading Up 0.2%

Shares of Arrowhead Pharmaceuticals stock traded up $0.13 during trading on Thursday, hitting $58.50. The stock had a trading volume of 2,009,461 shares, compared to its average volume of 2,292,497. The firm’s fifty day simple moving average is $76.71 and its 200-day simple moving average is $75.99. The stock has a market cap of $8.24 billion, a PE ratio of -26.00 and a beta of 1.29. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals has a 12 month low of $36.57 and a 12 month high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The firm had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. During the same quarter last year, the business posted ($1.26) EPS. Arrowhead Pharmaceuticals’s revenue was up 171.0% compared to the same quarter last year. As a group, sell-side analysts expect that Arrowhead Pharmaceuticals will post -3.62 EPS for the current fiscal year.

Insider Activity

In other news, Director Michael Perry sold 11,600 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the sale, the director owned 111,459 shares in the company, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Adeoye Olukotun sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the sale, the director owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. This represents a 5.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Sax Wealth Advisors LLC purchased a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at $624,000. GAMMA Investing LLC raised its position in shares of Arrowhead Pharmaceuticals by 17.1% in the third quarter. GAMMA Investing LLC now owns 4,542 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 663 shares during the last quarter. QRG Capital Management Inc. raised its position in shares of Arrowhead Pharmaceuticals by 7.1% in the second quarter. QRG Capital Management Inc. now owns 4,810 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 317 shares during the last quarter. Integrated Wealth Concepts LLC raised its position in shares of Arrowhead Pharmaceuticals by 5.2% in the second quarter. Integrated Wealth Concepts LLC now owns 8,297 shares of the biotechnology company’s stock valued at $676,000 after buying an additional 412 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $20,859,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported Phase 1/2a interim data showing deep and durable tau reductions of up to 73% in healthy volunteers. The results represent an early clinical validation that the company’s RNAi technology can deliver siRNA across the blood-brain barrier, a major challenge in developing neurological treatments. Arrowhead ARO-MAPT interim Phase 1/2a clinical data
• Positive Sentiment: The ARO-MAPT announcement prompted favorable coverage, with investors viewing the data as potentially establishing a new platform for treating Alzheimer’s and other tauopathies. Arrowhead reports positive ARO-MAPT data
• Positive Sentiment: UBS initiated coverage with a Buy rating and a $109 price target. Chardan Capital reaffirmed its Buy rating with a $115 target, while HC Wainwright maintained its Buy rating and raised or reiterated a $120 target. These targets imply substantial upside and reinforce the bullish view among analysts.
• Neutral Sentiment: The ARO-MAPT findings are still early-stage and were reported in healthy volunteers; they demonstrate tau knockdown and blood-brain-barrier delivery, but not yet clinical benefits for Alzheimer’s patients. Further trials will need to establish safety, efficacy, and commercial viability. Arrowhead discusses ARO-MAPT interim results and TRiM CNS delivery

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.